3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Recurrence
1
Ovarian Neoplasms
1
Gliosarcoma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Interventions
Carboplatin
16
Paclitaxel
9
Cyclophosphamide
8
liposomal doxorubicin
6
Peripheral Blood Stem Cell Transplantation
6
Topotecan
5
Filgrastim
5
pembrolizumab
4
Docetaxel
4
oregovomab
3
veliparib
2
sacituzumab govitecan
2
epacadostat
2
avelumab
2
Thiotepa
2
Taxes
2
STA 9090
2
Nivolumab
2
Erlotinib Hydrochloride
2
Drug Therapy
2
Cisplatin
2
Amifostine
2
talazoparib
1
ribociclib
1
relacorilant
1
ralimetinib
1
poly ICLC
1
phenoxodiol
1
peginterferon alfa-2b
1
pegfilgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Ovarian Epithelial
×
Palliative Care
×
Clear all
NCT07617753
2026-06-01
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled